{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:17:47Z","timestamp":1774959467211,"version":"3.50.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.clinthera.2005.06.015","type":"journal-article","created":{"date-parts":[[2005,8,23]],"date-time":"2005-08-23T18:13:25Z","timestamp":1124820805000},"page":"695-714","source":"Crossref","is-referenced-by-count":102,"title":["Acamprosate for the treatment of alcohol dependence"],"prefix":"10.1016","volume":"27","author":[{"given":"Lisa A.","family":"Boothby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul L.","family":"Doering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2005.06.015_bib1","unstructured":"Campral [package insert]. Available at: http:\/\/www.campral.com\/Campral_pi.pdf. Accessed February 1, 2005."},{"key":"10.1016\/j.clinthera.2005.06.015_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.drugalcdep.2004.02.004","article-title":"The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991\u20131992 and 2001\u20132002","volume":"74","author":"Grant","year":"2004","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.clinthera.2005.06.015_bib3","series-title":"Results from the 2002 National Survey on Drug Use and Health: National Findings","year":"2003"},{"key":"10.1016\/j.clinthera.2005.06.015_bib4","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)","first-page":"212","year":"2000"},{"key":"10.1016\/j.clinthera.2005.06.015_bib5","series-title":"Tenth Special Report to the US Congress on Alcohol and Health, 2000","article-title":"Treatment research","author":"National Institute on Alcohol Abuse and Alcoholism","year":"2000"},{"key":"10.1016\/j.clinthera.2005.06.015_bib6","doi-asserted-by":"crossref","first-page":"815","DOI":"10.7326\/0003-4819-133-10-200011210-00015","article-title":"Outpatient management of patients with alcohol problems","volume":"133","author":"Fiellin","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2005.06.015_bib7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/archinte.164.5.531","article-title":"US emergency department visits for alcohol-related diseases and injuries between 1992 and 2000","volume":"164","author":"McDonald","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2005.06.015_bib8","series-title":"Drug abuse warning network, 2003: Interim national estimates of drug-related emergency department visits","year":"2004"},{"key":"10.1016\/j.clinthera.2005.06.015_bib9","unstructured":"Alcohol, injuries, and the emergency department, Atlanta, Ga National Center for Injury Prevention and Control Available at: http:\/\/www.cdc.gov\/ncipc\/fact_book\/09_Alcohol_%20Injuries_%20ED.htm. Accessed June 6, 2005."},{"key":"10.1016\/j.clinthera.2005.06.015_bib10","unstructured":"Estimated economic costs of alcohol abuse in the United States, 1992 and 1998. Tenth Special Report to Congress on Alcohol and Health from the Secretary of Human Services (June 2000), DHHS Publication No. 00-1583. Adapted from Harwood H. Updating estimates of the economic costs of alcohol abuse in the United States: Estimates, update methods, and data; report prepared by the Lewin Group of the National Institute of Alcohol Abuse and Alcoholism, 2000; and Harwood H, Fountain H, and Livermore G. The economic costs of alcohol and drug abuse in the United States 1992. Report prepared for the National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services, NIH Publication No. 98-4327. Rockville, Md: National Institutes of Health; 1998. Available at: http:\/\/www.niaaa.nih.gov\/databases\/cost8.htm. Accessed June 6, 2005."},{"key":"10.1016\/j.clinthera.2005.06.015_bib11","series-title":"The Addictive Behaviors: Treatment of Alcoholism, Drug Abuse, Smoking, and Obesity","article-title":"Treating the problem drinker: Modern approaches","author":"Miller","year":"1980"},{"key":"10.1016\/j.clinthera.2005.06.015_bib12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.15288\/qjsa.1974.35.523","article-title":"A review of psychologically oriented treatment of alcoholism. I. The use and interrelationships of outcome criteria and drinking behavior following treatment","volume":"35","author":"Emrick","year":"1974","journal-title":"QJ Stud Alcohol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib13","series-title":"1988 Surgeon General's Report on Health Consequences of Smoking","article-title":"Relapse in the addictions: Rates, determinants, and promising relapse prevention strategies","author":"Catalano","year":"1988"},{"key":"10.1016\/j.clinthera.2005.06.015_bib14","series-title":"Handbook of Alcoholism Treatment Approaches","first-page":"12","article-title":"What works? A methodological analysis of the alcohol treatment outcome literature","author":"Miller","year":"1995"},{"key":"10.1016\/j.clinthera.2005.06.015_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00129785-200303040-00001","article-title":"Pharmacogenomics of alcohol response and addiction","volume":"3","author":"Enoch","year":"2003","journal-title":"Am J Pharmacogenomics"},{"key":"10.1016\/j.clinthera.2005.06.015_bib16","first-page":"208","article-title":"Defining alcohol-related phenotypes in humans","volume":"26","author":"Bierut","year":"2002","journal-title":"Alcohol Res Health"},{"key":"10.1016\/j.clinthera.2005.06.015_bib17","first-page":"193","article-title":"Effects of the interaction between genotype and environment. Research into the genetic epidemiology of alcohol dependence","volume":"26","author":"Heath","year":"2002","journal-title":"Alcohol Res Health"},{"key":"10.1016\/j.clinthera.2005.06.015_bib18","first-page":"489","article-title":"Pharmaco-genetics of alcohol response and alcoholism: The interplay of genes and environmental factors in thresholds for alcoholism","volume":"29","author":"Radel","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2005.06.015_bib19","series-title":"Substance Abuse: A Comprehensive Textbook","first-page":"119","article-title":"Alcohol: Neurobiology","author":"Valenzuela","year":"1997"},{"key":"10.1016\/j.clinthera.2005.06.015_bib20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jama.1997.03550020076042","article-title":"Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline","volume":"278","author":"Mayo-Smith","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2005.06.015_bib21","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","article-title":"A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence","volume":"56","author":"Mason","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2005.06.015_bib22","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.281.14.1318","article-title":"Pharmacological treatment of alcohol dependence: A review of the evidence","volume":"281","author":"Garbutt","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2005.06.015_bib23","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/ajhp\/61.22.2380","article-title":"Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 2","volume":"61","author":"Kenna","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2005.06.015_bib24","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1093\/ajhp\/61.21.2272","article-title":"Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1","volume":"61","author":"Kenna","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2005.06.015_bib25","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","article-title":"Disulfiram treatment of alcoholism. A Veterans Administration cooperative study","volume":"256","author":"Fuller","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2005.06.015_bib26","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1046\/j.1360-0443.2001.961115654.x","article-title":"Naltrexone for alcohol dependence: A randomized controlled trial","volume":"96","author":"Morris","year":"2001","journal-title":"Addiction"},{"key":"10.1016\/j.clinthera.2005.06.015_bib27","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/01.ALC.0000139823.30096.52","article-title":"A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence","volume":"28","author":"Johnson","year":"2004","journal-title":"Alcohol Clin Exp Res."},{"key":"10.1016\/j.clinthera.2005.06.015_bib28","first-page":"1","article-title":"Acamprosate (Campral) for alcoholism. The Medical Letter on Drugs and Therapeutics","volume":"47","year":"2005","journal-title":"Med Lett."},{"issue":"1","key":"10.1016\/j.clinthera.2005.06.015_bib29","first-page":"CD001867","article-title":"Opioid antagonists for alcohol dependence","author":"Srisurapanont","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2005.06.015_bib30","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archpsyc.61.9.905","article-title":"Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: A randomized controlled trial","volume":"61","author":"Johnson","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2005.06.015_bib31","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: A randomised controlled trial","volume":"361","author":"Johnson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2005.06.015_bib32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01.ALC.0000113409.47937.6C","article-title":"Development of novel pharmacotherapies for the treatment of alcohol dependence: Focus on antiepileptics","volume":"28","author":"Johnson","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2005.06.015_bib33","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1517\/14656566.5.9.1943","article-title":"An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence","volume":"5","author":"Johnson","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2005.06.015_bib34","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.ALC.0000134533.96915.08","article-title":"Progress in the development of topiramate for treating alcohol dependence: From a hypothesis to a proof-of-concept study","volume":"28","author":"Johnson","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2005.06.015_bib35","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.addbeh.2004.06.014","article-title":"Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: A new vista for the treatment of comorbid alcohol and nicotine dependence?","volume":"29","author":"Johnson","year":"2004","journal-title":"Addict Behav"},{"key":"10.1016\/j.clinthera.2005.06.015_bib36","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1360-0443.1995.tb01088.x","article-title":"Acamprosate in alcohol dependence: How does it work?","volume":"90","author":"Littleton","year":"1995","journal-title":"Addiction"},{"key":"10.1016\/j.clinthera.2005.06.015_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0741-8329(00)00137-3","article-title":"Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption","volume":"23","author":"Stromberg","year":"2001","journal-title":"Alcohol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib38","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/sj.npp.1300175","article-title":"Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats","volume":"28","author":"Heyser","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2005.06.015_bib39","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1440-1819.2004.01189.x","article-title":"Effect of the combination of naltrexone and acamprosate on alcohol intake in mice","volume":"58","author":"Kim","year":"2004","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.clinthera.2005.06.015_bib40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000077944","article-title":"Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence","volume":"50","author":"Boeijinga","year":"2004","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.clinthera.2005.06.015_bib41","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0301-0082(99)00031-3","article-title":"Ethanol and amino acids in the central nervous system: Assessment of the pharmacological actions of acamprosate","volume":"60","author":"Dahchour","year":"2000","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib42","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.2165\/00003495-199753060-00008","article-title":"Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification","volume":"53","author":"Wilde","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2005.06.015_bib43","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000026691","article-title":"Acamprosate reduces motor cortex excitability determined by transcranial magnetic stimulation","volume":"42","author":"Wohlfarth","year":"2000","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.clinthera.2005.06.015_bib44","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/alcalc\/33.6.602","article-title":"Improved autonomic neurocardial balance in short-term abstinent alcoholics treated with acamprosate","volume":"33","author":"Agelink","year":"1998","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1530-0277.1998.tb03636.x","article-title":"Acamprosate enhances N-methyl-D-aspartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons","volume":"22","author":"Berton","year":"1998","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2005.06.015_bib46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0925-4927(98)00016-X","article-title":"Central effects of acamprosate: Part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats","volume":"82","author":"Dahchour","year":"1998","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.clinthera.2005.06.015_bib47","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0028-3908(01)00008-9","article-title":"The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801","volume":"40","author":"Rammes","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.clinthera.2005.06.015_bib48","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s00210-003-0795-3","article-title":"Acamprosate blocks the increase in dopamine extracellular levels in nucleus accumbens evoked by chemical stimulation of the ventral hippocampus","volume":"368","author":"Cano-Cebrian","year":"2003","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0925-4927(98)00017-1","article-title":"Central effects of acamprosate: Part 2. Acamprosate modifies the brain invivo proton magnetic resonance spectrum in healthy young male volunteers","volume":"82","author":"Bolo","year":"1998","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.clinthera.2005.06.015_bib50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00210-002-0674-3","article-title":"Local acamprosate modulates dopamine release in the rat nucleus accumbens through NMDA receptors: An in vivo microdialysis study","volume":"367","author":"Cano-Cebrian","year":"2003","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib51","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1111\/j.1530-0277.2002.tb02484.x","article-title":"Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors","volume":"26","author":"Harris","year":"2002","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2005.06.015_bib52","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.ALC.0000056617.68874.18","article-title":"Effects of acamprosate on excitatory amino acids during multiple ethanol withdrawal periods","volume":"27","author":"Dahchour","year":"2003","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2005.06.015_bib53","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0014-2999(02)01272-4","article-title":"Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release","volume":"437","author":"Olive","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib54","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00003088-199835050-00001","article-title":"Clinical pharmacokinetics of acamprosate","volume":"35","author":"Saivin","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2005.06.015_bib55","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1530-0277.2002.tb02535.x","article-title":"Central nervous system mechanisms in alcohol relapse","volume":"26","author":"McBride","year":"2002","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2005.06.015_bib56","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/1355621031000117464","article-title":"A pilot study on the effects of treatment with acamprosate on craving for alcohol in alcohol-dependent patients","volume":"8","author":"Weinstein","year":"2003","journal-title":"Addict Biol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib57","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1037\/1064-1297.9.3.343","article-title":"Effects of contextual priming on reactions to craving and withdrawal stimuli in alcohol-dependent participants","volume":"9","author":"Feldtkeller","year":"2001","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib58","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1530-0277.2002.tb02452.x","article-title":"The European NEAT Program: An integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction","volume":"26","author":"Pelc","year":"2002","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2005.06.015_bib59","first-page":"239","article-title":"Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol","volume":"30","author":"Paille","year":"1995","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.clinthera.2005.06.015_sbref570","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archpsyc.1996.01830080023006","article-title":"Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence","volume":"53","author":"Sass","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2005.06.015_sbref580","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archpsyc.1996.01830080023006","volume":"53","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2005.06.015_bib61","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0140-6736(96)91682-7","article-title":"Comparison of acamprosate and placebo in long-term treatment of alcohol dependence","volume":"347","author":"Whitworth","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2005.06.015_bib62","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1192\/bjp.171.1.73","article-title":"Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study","volume":"171","author":"Pelc","year":"1997","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.clinthera.2005.06.015_bib63","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/alcalc\/35.2.176","article-title":"United Kingdom Multicentre Acamprosate Study (UKMAS): A 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol","volume":"35","author":"Chick","year":"2000","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib64","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/alcalc\/agg038","article-title":"Acamprosate in Korean alcohol-dependent patients: A multi-centre, randomized, double-blind, placebo-controlled study","volume":"38","author":"Namkoong","year":"2003","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib65","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00787-003-0327-1","article-title":"Acamprosate and its efficacy in the treatment of alcohol dependent adolescents","volume":"12","author":"Niederhofer","year":"2003","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.clinthera.2005.06.015_bib66","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/01.ALC.0000078020.92938.0B","article-title":"Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): A pilot feasibility study","volume":"27","year":"2003","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2005.06.015_bib67","doi-asserted-by":"crossref","first-page":"136","DOI":"10.15288\/jsa.2004.65.136","article-title":"Acamprosate in alcohol dependence: A randomized controlled efficacy study in a standard clinical setting","volume":"65","author":"Baltieri","year":"2004","journal-title":"J Stud Alcohol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib68","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/alcalc\/agh056","article-title":"A comparison of two intensities of psychosocial intervention for alcohol dependent patients treated with acamprosate","volume":"39","author":"Hammarberg","year":"2004","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib69","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/alcalc\/agh088","article-title":"A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care","volume":"39","author":"Kiritze-Topor","year":"2004","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00126839-200203010-00001","article-title":"Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study","volume":"3","author":"Soyka","year":"2002","journal-title":"Drugs R D"},{"key":"10.1016\/j.clinthera.2005.06.015_bib71","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/alcalc\/37.4.375","article-title":"Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems?","volume":"37","author":"De Wildt","year":"2002","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib72","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.ALC.0000108656.81563.05","article-title":"The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis","volume":"28","author":"Mann","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2005.06.015_bib73","first-page":"811","article-title":"Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review [published correction appears in Addiction. 2005;100:573]","volume":"99","author":"Bouza","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.clinthera.2005.06.015_bib74","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1530-0277.2001.tb02356.x","article-title":"Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis","volume":"25","author":"Kranzler","year":"2001","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2005.06.015_bib75","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2005.06.015_bib76","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/bmj.309.6965.1351","article-title":"Why sources of heterogeneity in meta-analysis should be investigated","volume":"309","author":"Thompson","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2005.06.015_bib77","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","article-title":"Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: A double-blind, placebo-controlled study","volume":"60","author":"Kiefer","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2005.06.015_bib78","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1530-0277.1998.tb04295.x","article-title":"Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: A controlled study","volume":"22","author":"Besson","year":"1998","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2005.06.015_bib79","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.ALC.0000108652.73143.4B","article-title":"Improvement in quality of life after treatment for alcohol dependence with acamprosate and psychosocial support","volume":"28","author":"Morgan","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2005.06.015_bib80","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2515\/therapie:2003057","article-title":"[Acamprosate (Aotal): Could adverse effects upset the treatment of alcohol dependence? (published corection appears in Therapie. 2003;58:474)]","volume":"58","author":"Oscar","year":"2003","journal-title":"Therapie"},{"key":"10.1016\/j.clinthera.2005.06.015_bib81","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/0140-6736(92)91568-S","article-title":"Possible association of erythema multiforme with acamprosate","volume":"339","author":"Fortier-Beaulieu","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2005.06.015_bib82","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/0140-6736(92)92738-2","article-title":"Acamprosate as cause of erythema multiforme contested","volume":"340","author":"Potgieter","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2005.06.015_bib83","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1345\/aph.1A034","article-title":"FDA labeling system for drugs in pregnancy","volume":"35","author":"Boothby","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2005.06.015_bib84","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1067\/mob.2002.125740","article-title":"Review of pregnancy labeling of prescription drugs: Is the current system adequate to inform of risks?","volume":"187","author":"Doering","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib85","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0893-133X(02)00368-8","article-title":"A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone","volume":"27","author":"Mason","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2005.06.015_bib86","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/01.ALC.0000130802.07692.29","article-title":"Alcohol effects during acamprosate treatment: A doseresponse study in humans","volume":"28","author":"Brasser","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2005.06.015_bib87","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/alcalc\/36.5.413","article-title":"Acamprosate during and after acute alcohol with-drawal: A double-blind placebo-controlled study in Spain","volume":"36","author":"Gual","year":"2001","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.clinthera.2005.06.015_bib88","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0740-5472(03)00039-4","article-title":"Factors associated with the receipt of treatment following detoxification","volume":"24","author":"Mark","year":"2003","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.clinthera.2005.06.015_bib89","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1521-0391.2003.tb00543.x","article-title":"Barriers to the use of medications to treat alcoholism","volume":"12","author":"Mark","year":"2003","journal-title":"Am J Addict"},{"key":"10.1016\/j.clinthera.2005.06.015_bib90","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1360-0443.2003.00377.x","article-title":"Physicians' opinions about medications to treat alcoholism","volume":"98","author":"Mark","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.clinthera.2005.06.015_bib91","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0376-8716(03)00134-0","article-title":"Understanding US addiction physicians' low rate of naltrexone prescription","volume":"71","author":"Mark","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.clinthera.2005.06.015_bib92","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1046\/j.1524-4733.2003.64247.x","article-title":"Using stated preference modeling to forecast the effect of medication attributes on prescriptions of alcoholism medications","volume":"6","author":"Mark","year":"2003","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2005.06.015_bib93","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1176\/appi.ps.54.8.1095","article-title":"The costs of treating persons with depression and alcoholism compared with depression alone","volume":"54","author":"Mark","year":"2003","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.clinthera.2005.06.015_bib94","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0740-5472(03)00161-2","article-title":"Beliefs about evidence-based practices in addiction treatment: A survey of Veterans Administration program leaders","volume":"26","author":"Willenbring","year":"2004","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.clinthera.2005.06.015_bib95","series-title":"Drug Topics Red Book: April 2005 Update","year":"2005"},{"key":"10.1016\/j.clinthera.2005.06.015_bib96","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000068810","article-title":"Cost-effectiveness of adjuvant treatment with acamprosate in maintaining abstinence in alcohol dependent patients","volume":"9","author":"Rychlik","year":"2003","journal-title":"Eur Addict Res"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805001086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805001086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T11:06:06Z","timestamp":1626433566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291805001086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":97,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0149291805001086"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2005.06.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}